Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics (NASDAQ:SONN) has released a Virtual Investor 'What This Means' segment featuring discussions with Interim CEO Raghu Rao and Chief Medical Officer Dr. Richard Kenney. The segment focuses on recently announced positive safety results for SON-1010 (IL12-FHAB) in combination with atezolizumab at its highest dose level.
The clinical trial in question is a Phase 1b/2a study (SB221) evaluating the treatment in adult patients with advanced solid tumors or platinum-resistant ovarian cancer (PROC). The management team provided insights into the program's future steps during the presentation.
Sonnet BioTherapeutics (NASDAQ:SONN) ha pubblicato un segmento virtuale per investitori intitolato 'Cosa Significa', con interventi dell'Amministratore Delegato ad interim Raghu Rao e del Direttore Medico Dr. Richard Kenney. Il segmento si concentra sui risultati positivi di sicurezza recentemente annunciati per SON-1010 (IL12-FHAB) in combinazione con atezolizumab al dosaggio più elevato.
Lo studio clinico in questione è una sperimentazione di Fase 1b/2a (SB221) che valuta il trattamento in pazienti adulti con tumori solidi avanzati o cancro ovarico resistente al platino (PROC). Il team di gestione ha fornito indicazioni sui prossimi passi del programma durante la presentazione.
Sonnet BioTherapeutics (NASDAQ:SONN) ha lanzado un segmento virtual para inversores titulado 'Qué Significa Esto', con conversaciones con el CEO interino Raghu Rao y el Director Médico Dr. Richard Kenney. El segmento se centra en los resultados positivos de seguridad recientemente anunciados para SON-1010 (IL12-FHAB) en combinación con atezolizumab en su dosis más alta.
El ensayo clínico en cuestión es un estudio de Fase 1b/2a (SB221) que evalúa el tratamiento en pacientes adultos con tumores sólidos avanzados o cáncer de ovario resistente al platino (PROC). El equipo directivo ofreció perspectivas sobre los próximos pasos del programa durante la presentación.
Sonnet BioTherapeutics (NASDAQ:SONN)는 임시 CEO 라구 라오(Raghu Rao)와 최고 의학 책임자 리처드 케니 박사(Dr. Richard Kenney)와의 대화를 담은 가상 투자자 '이 의미는 무엇인가' 세그먼트를 공개했습니다. 이 세그먼트는 SON-1010(IL12-FHAB)과 아테졸리주맙의 최고 용량 병용에 대한 최근 발표된 안전성 긍정 결과에 초점을 맞추고 있습니다.
해당 임상 시험은 성인 환자의 진행성 고형암 또는 플래티넘 내성 난소암(PROC)을 평가하는 1b/2a상 연구(SB221)입니다. 경영진은 발표 중 프로그램의 향후 단계에 대한 통찰을 제공했습니다.
Sonnet BioTherapeutics (NASDAQ:SONN) a publié un segment virtuel pour investisseurs intitulé « Ce que cela signifie », avec des interventions du PDG par intérim Raghu Rao et du directeur médical Dr Richard Kenney. Ce segment se concentre sur les résultats positifs en matière de sécurité récemment annoncés pour SON-1010 (IL12-FHAB) en combinaison avec l’atezolizumab à la dose la plus élevée.
L’essai clinique en question est une étude de phase 1b/2a (SB221) évaluant le traitement chez des patients adultes atteints de tumeurs solides avancées ou de cancer de l’ovaire résistant au platine (PROC). L’équipe de direction a donné des indications sur les prochaines étapes du programme lors de la présentation.
Sonnet BioTherapeutics (NASDAQ:SONN) hat ein virtuelles Investoren-Segment mit dem Titel 'Was das bedeutet' veröffentlicht, in dem Gespräche mit dem Interim-CEO Raghu Rao und dem Chief Medical Officer Dr. Richard Kenney geführt werden. Das Segment konzentriert sich auf die kürzlich bekannt gegebenen positiven Sicherheitsdaten für SON-1010 (IL12-FHAB) in Kombination mit Atezolizumab in der höchsten Dosierung.
Die betreffende klinische Studie ist eine Phase 1b/2a-Studie (SB221), die die Behandlung bei erwachsenen Patienten mit fortgeschrittenen soliden Tumoren oder platinhaltigem resistentem Eierstockkrebs (PROC) bewertet. Das Management-Team gab während der Präsentation Einblicke in die nächsten Schritte des Programms.
- Positive safety results achieved for SON-1010 at highest dose level
- Successfully advancing Phase 1b/2a clinical trial
- None.
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
- Watch the "What This Means" video here
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team participated in a Virtual Investor "What This Means" segment.
As part of the segment, Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, discussed the recently announced positive safety results of SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab being evaluated in the Phase 1b/2a clinical trial in adult patients with advanced solid tumors or platinum-resistant ovarian cancer (PROC) (the SB221 study). Mr. Rao and Dr. Kenney also provided insight into next steps for the program.
The Virtual Investor "What This Means" segment featuring Sonnet is now available here.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC) (NCT05756907). The Company is also evaluating its second program using this platform, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
SONN@jtcir.com
FAQ
What are the latest safety results for Sonnet's SON-1010 clinical trial (SONN)?
What type of cancer patients are included in Sonnet's SB221 clinical trial?
What is the current development phase of Sonnet's SON-1010 drug?
What is SON-1010's mechanism of action in cancer treatment?
